Kerry Wentworth, who serves as Chief Regulatory Officer for Nuvation Bio Inc (NASDAQ: NUVB), completed a pair of related equity transactions on April 6, 2026. On that date Wentworth sold 200,000 shares of the company’s Class A Common Stock for aggregate proceeds of $903,560.
The sale was executed at a weighted-average price of $4.5178 per share, with individual trade prices reported in a range from $4.44 to $4.64.
Concurrently, Wentworth exercised stock options to acquire 200,000 Class A shares of Nuvation Bio. The exercise comprised two tranches of 100,000 shares apiece: one tranche at an exercise price of $1.87 per share and the second at $1.94 per share. The combined cost to exercise those options was $381,000.
Following the sale and the option exercises, Wentworth’s direct ownership in Nuvation Bio stands at 53,000 shares.
Market context and recent performance
Over the trailing 12 months the stock has delivered a total return of 172%, although the shares have fallen 50% year-to-date. Independent valuation analysis cited in public reporting indicates that NUVB is trading below its calculated Fair Value, a position that some interpret as implying potential upside, even as volatility has increased.
That analysis is available through a subscription platform which provides additional ProTips and financial metrics for investors seeking a deeper view beyond headline insider activity.
Corporate and regulatory developments
Nuvation Bio has been active on multiple fronts in recent weeks. The company announced an amendment to its exclusive license agreement with Daiichi Sankyo that secures global development and commercialization rights for safusidenib, and expands those rights to include Japan.
On the regulatory side, the European Medicines Agency has validated Nuvation Bio’s Marketing Authorization Application for taletrectinib, a therapy intended for patients with advanced ROS1-positive non-small cell lung cancer. That application will proceed through the EMA’s standard review process, and the company plans additional filings in the U.K., Canada and other jurisdictions.
Analyst coverage and price targets
Several brokerages have adjusted or reiterated their views on Nuvation Bio following these corporate and regulatory developments. Truist Securities reiterated a Buy rating and maintained a $12.00 price target. RBC Capital raised its price target to $20.00, citing the potential for meaningful revenue in the glioma market tied to the company’s safu candidate. H.C. Wainwright also reiterated a Buy rating and set a $17.00 price target.
Truist separately reaffirmed its Buy rating and the $12.00 target following meetings with Nuvation Bio management, noting discussions around the Ibtrozi launch and the safu glioma program.
Investor tools and screening
Separately, an AI-driven stock selection tool referenced in public materials evaluates NUVB alongside thousands of other companies using more than 100 financial metrics. That tool is described as using AI to identify stocks with favorable risk-reward profiles and highlights notable past winners in its universe, including Super Micro Computer (+185%) and AppLovin (+157%).
These transactions and company updates occur against a backdrop of mixed recent share performance and a cluster of analyst ratings that reflect optimism about the company’s commercial and regulatory prospects. The combination of insider option exercises, a significant personal sale and ongoing regulatory filings creates a set of developments market participants will likely track as they assess Nuvation Bio’s near-term outlook.